Press release
Psoriatic Arthritis Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Psoriatic Arthritis Treatment Landscape. Click here to read more @ Psoriatic Arthritis Pipeline Outlook [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Psoriatic Arthritis Pipeline Report
* In July 2025, UCB Biopharma SRL announced a study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
* In July 2025, AbbVie conducted a study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
* In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
* DelveInsight's Psoriatic Arthritis pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Psoriatic Arthritis treatment.
* The leading Psoriatic Arthritis Companies such as Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc . and others.
* Promising Psoriatic Arthritis Therapies such as NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, and others.
Discover groundbreaking developments in Psoriatic Arthritis therapies! Gain in-depth knowledge of key Psoriatic Arthritis clinical trials, emerging drugs, and market opportunities @ Psoriatic Arthritis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psoriatic Arthritis Emerging Drugs Profile
* Sotyktu: Bristol Myers Squibb
Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3. Currently, the drug is in the Phase III stage of its development for the treatment of Psoriasis Arthritis.
* HS-10374: Hansoh BioMedical R&D Company
HS-10374 mechanism of action is to inhibit (TYK2) that is tyrosine-kinase 2. TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation. Its route of administration is orally. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Psoriasis Arthritis.
* si-544: selection
si-544, the Companys lead candidate, selectively blocks Kv1.3, a key ion channel expressed disease-associated effector memory T (TEM) cells. Kv1.3 is essential for the chronic activation and proliferation of these cells which escape the control of the immune system and become malignant. TEM cells drive inflammation in many autoimmune diseases, including atopic dermatitis, psoriasis, rheumatoid arthritis, and multiple sclerosis. Currently, the drug is in the Phase I stage of its development for the treatment of Psoriasis Arthritis.
The Psoriatic Arthritis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Psoriatic Arthritis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis Treatment.
* Psoriatic Arthritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Psoriatic Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriatic Arthritis market
Stay informed about the Psoriatic Arthritis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Psoriatic Arthritis Unmet Needs [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Psoriatic Arthritis Companies
Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc. and others.
Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Intramuscular
* Topical
Psoriatic Arthritis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Psoriatic Arthritis Pipeline! See the latest progress in drug development and clinical research @ Psoriatic Arthritis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Psoriatic Arthritis Pipeline Report
* Coverage- Global
* Psoriatic Arthritis Companies- Pfizer, selectION Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi, Inc., Hansoh BioMedical R&D Company, Bio-Thera Solutions, Mylan Inc., ACELYRIN Inc . and others.
* Psoriatic Arthritis Pipeline Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, and others.
* Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Psoriatic Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research-Access the Full Psoriatic Arthritis Pipeline Analysis Today! @ Psoriatic Arthritis Drugs and Companies [https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Psoriatic Arthritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Psoriatic Arthritis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Sotyktu: Bristol Myers Squibb
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HS-10374: Hansoh BioMedical R&D Company
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* si-544: selection
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Psoriatic Arthritis Key Companies
* Psoriatic Arthritis Key Products
* Psoriatic Arthritis - Unmet Needs
* Psoriatic Arthritis - Market Drivers and Barriers
* Psoriatic Arthritis - Future Perspectives and Conclusion
* Psoriatic Arthritis Analyst Views
* Psoriatic Arthritis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriatic-arthritis-pipeline-outlook-report-2025-key-20-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriatic Arthritis Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4123599 • Views: …
More Releases from ABNewswire
Freelance Platforms Market Forecast to Reach USD 16.54 Billion by 2030, Driven b …
Mordor Intelligence has published a new report on the Freelance Platforms Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Freelance Platforms Market Outlook
The freelance platforms market size [https://www.mordorintelligence.com/industry-reports/freelance-platforms-market?utm_source=abnewswire] stands at USD 7.65 billion in 2025 and is forecast to reach USD 16.54 billion by 2030, advancing at a 16.66% CAGR. The Freelance Platforms Market share is currently dominated by platform models, while services are gaining momentum with…
Surprising Comparison: Disney vs. Taylor Swift Concert Costs
Disney World Ticket Prices Nearly Double Over Past Decade: PixieVacations Reveals Comprehensive Analysis and Money-Saving Strategies for 2025 Travelers
Walt Disney World ticket prices reach historic highs in 2025, with peak one-day Magic Kingdom tickets now exceeding $200 for the first time ever, PixieVacations.com has released a comprehensive analysis of Disney World ticket prices over the past decade. The leading Disney vacation planning service aims to help families navigate these rising…
Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology
Skin cancer is rarely viewed as life-changing, but for millions of patients each year, basal cell carcinoma brings a cycle of surgeries, scars, and slow recovery that feels endless. Hospitals are overloaded, dermatologists are booked months in advance, and treatments that remove tumors often leave lasting damage. The challenge is not identifying the cancer; it is finding a way to treat it without cutting the patient open. That is the…
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
More Releases for Arthritis
Rising Arthritis Cases Fueling Market Growth For Rheumatoid Arthritis Drugs: Piv …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Rheumatoid Arthritis Drugs Market Size Growth Forecast: What to Expect by 2025?
In recent years, there has been a slight decline in the rheumatoid arthritis drugs market size. It is projected to rise from "$60.3 billion in 2024 to $60.1 billion in 2025, with a compound annual growth rate…
Infectious Arthritis (Septic Arthritis) Market Detailed Industry Report Analysis …
Introduction
Infectious arthritis, also known as septic arthritis, is a serious joint condition caused by bacterial, viral, or fungal infections that lead to rapid joint destruction if not treated promptly. The disease primarily affects large joints such as the knee and hip but can also impact smaller joints. It is considered a medical emergency requiring rapid diagnosis and treatment with antibiotics or antifungals, often combined with joint drainage or surgical intervention.
The…
Nooro Arthritis Hand Massager Reviews: Is the Nooro Arthritis Hand Massager Wort …
The Nooro Arthritis Hand Massager is a revolutionary device designed to offer relief to individuals suffering from hand pain, particularly those dealing with conditions such as arthritis, carpal tunnel syndrome, and repetitive strain injuries. As hand pain can significantly impact daily activities, from typing to gripping objects, finding an effective, non-invasive solution is crucial. The Nooro Arthritis Hand Massager provides a gentle yet effective remedy by combining advanced heat therapy…
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers
Classification of Rheumatoid Arthritis Drugs
3.1…
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the…
Worldwide Arthritis - EpiCast Report: Rheumatoid Arthritis - Epidemiology Foreca …
"EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
Description-
** Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the bodys immune system attacks the lining of the joints, known as…
